Metagenomics In Healthcare Market Report 2026

Metagenomics In Healthcare Market Overview

• Metagenomics In Healthcare market size has reached to $2.44 billion in 2025 • Expected to grow to $5.46 billion in 2030 at a compound annual growth rate (CAGR) of 17.5% • Growth Driver: Increasing Prevalence Of Infectious Diseases Fueling The Growth Of The Market Due To Rising Pathogen Spread And Need For Rapid, Accurate Diagnostics • Market Trend: Innovative Solutions Drive Advanced Disease Diagnostics • North America was the largest region in 2025 and Asia-Pacific is the fastest growing region.

What Is Covered Under Metagenomics In Healthcare Market?

Metagenomics in healthcare is the study of genetic material recovered directly from clinical or environmental samples to analyze entire microbial communities without the need for culturing. It helps to identify pathogens, understand microbiome composition, and detect disease-associated microbial shifts, enabling precise diagnosis, personalized treatment, and improved infection management. The main types of metagenomics in healthcare are sample extraction kits and metagenomics kits. Sample extraction kits refer to commercially available kits designed to isolate deoxyribonucleic acid or ribonucleic acid from biological samples efficiently and reliably. It utilizes technologies, including next-generation sequencing, polymerase chain reaction, and microarray, and has different workflows including sample collection, deoxyribonucleic acid extraction, library preparation, and sequencing. It finds applications in infectious disease diagnosis, genomic epidemiology, personalized medicine, microbiome analysis, and drug discovery, serving end users such as hospitals, diagnostic laboratories, research institutes, pharmaceutical companies, and biotechnology companies.

What Is The Metagenomics In Healthcare Market Growth Forecast?

The metagenomics in healthcare market size is expected to see rapid growth in the next few years. It will grow to $5.46 billion in 2030 at a compound annual growth rate (CAGR) of 17.5%. The growth in the forecast period can be attributed to increasing adoption of precision infectious disease diagnostics, rising investments in microbiome therapeutics, expansion of genomic epidemiology initiatives, growing integration of ai in microbial analysis, increasing focus on personalized treatment strategies. Major trends in the forecast period include increasing adoption of metagenomic diagnostics in clinical settings, growing use of microbiome-based disease profiling, rising integration of ngs in infection management, expansion of personalized microbial therapeutics research, enhanced focus on rapid pathogen identification.

Global Metagenomics In Healthcare Market Segmentation

1) By Types: Sample Extraction Kits, Metagenomics Kits 2) By Technology: Next-Generation Sequencing, Polymerase Chain Reaction, Microarray 3) By Workflow: Sample Collection, Deoxyribonucleic Acid Extraction, Library Preparation, Sequencing 4) By Application: Infectious Disease Diagnosis, Genomic Epidemiology, Personalized Medicine, Microbiome Analysis, Drug Discovery 5) By End User: Hospitals, Diagnostic Laboratories, Research Institutes, Pharmaceutical Companies, Biotechnology Companies Subsegments: 1) By Sample Extraction Kits: Deoxyribonucleic Acid Extraction Kits, Ribonucleic Acid Extraction Kits, Protein Extraction Kits 2) By Metagenomics Kits: Library Preparation Kits, Sequencing Kits, Target Enrichment Kits

What Is The Driver Of The Metagenomics In Healthcare Market?

The increasing prevalence of infectious diseases is expected to propel the growth of metagenomics in healthcare market going forward. Infectious diseases refer to illnesses caused by harmful microorganisms such as bacteria, viruses, fungi, or parasites that can spread directly or indirectly from one person to another. The rising prevalence of infectious diseases is due to increased travel, which facilitates the rapid spread of pathogens across borders. Metagenomics in healthcare helps combat infectious diseases by enabling rapid and precise identification of pathogens, making it crucial for controlling infectious outbreaks. It reduces diagnostic uncertainty by analyzing complex microbial communities, improving patient outcomes, and guiding targeted treatments. For instance, in February 2024, according to the UK Health Security Agency, a UK-based government agency, tuberculosis (a contagious bacterial infection that primarily affects the lungs) cases in England rose to 4,850 in 2023, an increase of 10.7% from 4,380 cases in 2022. Therefore, the increasing prevalence of infectious diseases is driving the growth of the metagenomics in healthcare industry.

Key Players In The Global Metagenomics In Healthcare Market

Major companies operating in the metagenomics in healthcare market are F. Hoffmann-La Roche AG, Eurofins Scientific, Agilent Technologies Inc., Illumina Inc., Bio-Rad Laboratories Inc., QIAGEN N.V., BGI Genomics Co. Ltd., Novogene Corporation, Oxford Nanopore Technologies Limited, Pacific Biosciences of California Inc., MedGenome Labs Limited, Zymo Research Corporation, BaseClear B.V., Psomagen Inc., Karius Inc., Microsynth AG, Macrogen Inc., Norgen Biotek Corp., Tiny Health Inc., CosmosID Inc., Kanvas Biosciences Inc., Phase Genomics Inc., Wobble Genomics Inc.

Global Metagenomics In Healthcare Market Trends and Insights

Major companies operating in the metagenomics in healthcare market are focusing on developing innovative solutions, such as microbial community profiling, to enhance disease diagnostics, enable personalized therapies, and advance precision medicine. Microbial community profiling refers to the comprehensive analysis and characterization of diverse microbial populations within a specific environment or sample, using sequencing and bioinformatics tools to identify their composition, diversity, and functional roles. For instance, in August 2024, MGI Tech Co. Ltd., a China-based biotechnology company, launched a Human Microbiome Metagenomics Sequencing Package to advance microbial research and healthcare applications. It delivers an automated, end-to-end microbial community profiling workflow for efficiently analyzing human microbiome diversity, function, and disease links using validated high-throughput platforms. It minimizes manual labor, enhances reproducibility, and reduces costs, making large-scale and clinical microbiome research more accessible. The researchers gain advantages from fast and precise microbial identification, along with adaptable throughput, facilitating biomarker discovery and advancing translational health research.

What Are Latest Mergers And Acquisitions In The Metagenomics In Healthcare Market?

In May 2025, Mapmygenome India Limited, an India-based genomics and diagnostics company, acquired Microbiome Insights Inc. for an undisclosed amount. With this acquisition, Mapmygenome aims to expand its capabilities in microbiome sequencing and analysis, strengthen its presence in the North American market, and enhance its offerings in personalized health, genomics, and research services. Microbiome Insights Inc. is a Canada-based biotechnology company that offers metagenomics in healthcare.

Regional Outlook

North America was the largest region in the metagenomics in healthcare market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in this market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in this market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

What Defines the Metagenomics In Healthcare Market?

The metagenomics in healthcare market consists of revenues earned by entities by providing services such as bioinformatics analysis, microbial diagnostics, and drug discovery support. The market value includes the value of related goods sold by the service provider or included within the service offering. The metagenomics in the healthcare market also includes sales of sequencing platforms, reagents, consumables, and bioinformatics tools. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

How is Market Value Defined and Measured?

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

What Key Data and Analysis Are Included in the Metagenomics In Healthcare Market Report 2026?

The metagenomics in healthcare market research report is one of a series of new reports from The Business Research Company that provides market statistics, including industry global market size, regional shares, competitors with the market share, detailed market segments, market trends and opportunities, and any further data you may need to thrive in the metagenomics in healthcare industry. The market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future state of the industry.